find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
351
Clinical Trials
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / BTKI/IIT
Use of Bruton tyrosine kinase inhibitors (BTKI) in patients with Waldenstrom macroglobulinemia (WM) with neuropathy and Bing-Neel syndrome, and non-IgM lymphoplasmacytic lymphoma
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / BIOLOGICAL-SPECIMEN
Collection of Biological Specimens from Volunteers or Patients with Multiple Myeloma and other Plasma Cell Dyscrasias
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / BI-SPECIFIC-T-CELL-OUTCOMES
Outcomes of Multiple Myeloma Patients who are Refractory to Bi-Specific T-Cell Engagers
Learn More
Multiple Myeloma
Phase I
Enrolling
nct/study# NCT04973605 / BGB-11417-105
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / BCMA/IIT
Real-World Experience with BCMA-directed therapies for patients with relapsed and refractory multiple myeloma.
Learn More
Multiple Myeloma
Phase I
Enrolling
nct/study# NCT05651932 / K-36-KTX-MMSET-001
A Phase 1 Study of an oral, first-in-class, selective, and potent MMSET catalytic inhibitor that suppresses H3K36me2 in patients with Relapsed and Refractory Multiple Myeloma
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.